Bone marrow (BM)-derived mesenchymal stromal cells (MSCs), endowed with immunosuppressive and anti-inflammatory properties, represent a promising tool in immunoregulatory and regenerative cell therapy. Clarifying the interactions between MSCs and B-lymphocytes may be crucial for designing innovative MSC-based strategies in conditions in which B cells play a role, including systemic lupus erythematosus (SLE) and rejection of kidney transplantation. In this study, we show that, both in healthy subjects and in patients, in vitro B-cell proliferation, plasma-cell differentiation, and antibody production are inhibited by BM-derived MSCs when peripheral blood lymphocytes are stimulated with CpG, but not when sorted B cells are cultured with MSCs+CpG. Inhibition is restored in CpG+MSC cocultures when sorted T cells are added to sorted B cells, suggesting that this effect is mediated by T cells, with both CD4+ and CD8+ cells playing a role. Moreover, cell–cell contact between MSCs and T cells, but not between MSCs and B cells, is necessary to inhibit B-cell proliferation. Thus, the presence of functional T cells, as well as cell–cell contact between MSCs and T cells, are crucial for B-cell inhibition. This information can be relevant for implementing MSC-based therapeutic immune modulation in patients in whom T-cell function is impaired.
Get full access to this article
View all access options for this article.
References
1.
HorwitzEM, Le BlancK, DominiciM, MuellerI, Slaper-CortenbachI, MariniFC, DeansRJ, KrauseDS and KeatingA. (2005). Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy, 7:393–395.
2.
FriedensteinAJ, DeriglasovaUF, KulaginaNN, PanasukAF, RudakowaSF, LuriaEA and RuadkowIA. (1974). Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol, 2:83–92.
3.
FiorinaP, JurewiczM, AugelloA, VerganiA, DadaS, La RosaS, SeligM, GodwinJ, LawK, et al. (2009). Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol, 183:993–1004.
4.
FranquesaM, HerreroE, TorrasJ, RipollE, FlaquerM, GomaM, LloberasN, AnegonI, CruzadoJM, GrinyoJM and Herrero-FresnedaI. (2012). Mesenchymal stem cell therapy prevents interstitial fibrosis and tubular atrophy in a rat kidney allograft model. Stem Cells Dev, 21:3125–3135.
5.
LocatelliF, MaccarioR and FrassoniF. (2007). Mesenchymal stromal cells, from indifferent spectators to principal actors. Are we going to witness a revolution in the scenario of allograft and immune-mediated disorders?. Haematologica, 92:872–877.
6.
NautaAJ and FibbeWE. (2007). Immunomodulatory properties of mesenchymal stromal cells. Blood, 110:3499–3506.
7.
UccelliA, PistoiaV and MorettaL. (2007). Mesenchymal stem cells: a new strategy for immunosuppression?. Trends Immunol, 28:219–226.
8.
FranquesaM, HoogduijnMJ, BestardO and GrinyoJM. (2012). Immunomodulatory effect of mesenchymal stem cells on B cells. Front Immunol, 3:212
KramperaM, CosmiL, AngeliR, PasiniA, LiottaF, AndreiniA, SantarlasciV, MazzinghiB, PizzoloG, et al. (2006). Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells, 24:386–398.
11.
TraggiaiE, VolpiS, SchenaF, GattornoM, FerlitoF, MorettaL and MartiniA. (2008). Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells, 26:562–569.
12.
BernardoME, PagliaraD and LocatelliF. (2012). Mesenchymal stromal cell therapy: a revolution in regenerative medicine?. Bone Marrow Transplant, 47:164–171.
13.
WiseAF and RicardoSD. (2012). Mesenchymal stem cells in kidney inflammation and repair. Nephrology (Carlton), 17:1–10.
14.
BernardoME and FibbeWE. (2012). Safety and efficacy of mesenchymal stromal cell therapy in autoimmune disorders. Ann N Y Acad Sci, 1266:107–117.
15.
SchenaF, GambiniC, GregorioA, MosconiM, ReverberiD, GattornoM, CasazzaS, UccelliA, MorettaL, MartiniA and TraggiaiE. (2010). Interferon-gamma-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. Arthritis Rheum, 62:2776–2786.
16.
ZhouK, ZhangH, JinO, FengX, YaoG, HouY and SunL. (2008). Transplantation of human bone marrow mesenchymal stem cell ameliorates the autoimmune pathogenesis in MRL/lpr mice. Cell Mol Immunol, 5:417–424.
17.
CapolunghiF, CascioliS, GiordaE, RosadoMM, PlebaniA, AuritiC, SegantiG, ZuntiniR, FerrariS, et al. (2008). CpG drives human transitional B cells to terminal differentiation and production of natural antibodies. J Immunol, 180:800–808.
18.
AranburuA, CeccarelliS, GiordaE, LasorellaR, BallatoreG and CarsettiR. (2010). TLR ligation triggers somatic hypermutation in transitional B cells inducing the generation of IgM memory B cells. J Immunol, 185:7293–7301.
19.
CapolunghiF, RosadoMM, CascioliS, GirolamiE, BordascoS, VivarelliM, RuggieroB, CortisE, InsalacoA, et al. (2010). Pharmacological inhibition of TLR9 activation blocks autoantibody production in human B cells from SLE patients. Rheumatology (Oxford), 49:2281–2289.
20.
VasilescuER, HoEK, ColovaiAI, VladG, Foca-RodiA, MarkowitzGS, D'AgatiV, HardyMA, RatnerLE and Suciu-FocaN. (2006). Alloantibodies and the outcome of cadaver kidney allografts. Hum Immunol, 67:597–604.
21.
AggarwalS and PittengerMF. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood, 105:1815–1822.
22.
Di IanniM, Del PapaB, De IoanniM, MorettiL, BonifacioE, CecchiniD, SportolettiP, FalzettiF and TabilioA. (2008). Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol, 36:309–318.
23.
MaccarioR, PodestaM, MorettaA, CometaA, ComoliP, MontagnaD, DaudtL, IbaticiA, PiaggioG, et al. (2005). Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica, 90:516–525.
24.
LeonardoSM, De SantisJL, MalherbeLP and GauldSB. (2012). Cutting edge: in the absence of regulatory T cells, a unique Th cell population expands and leads to a loss of B cell anergy. J Immunol, 188:5223–5226.
25.
ChoiJ, KimST and CraftJ. (2012). The pathogenesis of systemic lupus erythematosus-an update. Curr Opin Immunol, 24:651–657.
26.
ComoliP, GinevriF, MaccarioR, AvanziniMA, MarconiM, GroffA, CometaA, CioniM, PorrettiL, et al. (2008). Human mesenchymal stem cells inhibit antibody production induced in vitro by allostimulation. Nephrol Dial Transplant, 23:1196–1202.
27.
NankivellBJ and AlexanderSI. (2010). Rejection of the kidney allograft. N Engl J Med, 363:1451–1462.
28.
CarrionF, NovaE, LuzP, ApablazaF and FigueroaF. (2011). Opposing effect of mesenchymal stem cells on Th1 and Th17 cell polarization according to the state of CD4+ T cell activation. Immunol Lett, 135:10–16.
29.
WangQ, SunB, WangD, JiY, KongQ, WangG, WangJ, ZhaoW, JinL and LiH. (2008). Murine bone marrow mesenchymal stem cells cause mature dendritic cells to promote T-cell tolerance. Scand J Immunol, 68:607–615.
30.
SpaggiariGM, AbdelrazikH, BecchettiF and MorettaL. (2009). MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood, 113:6576–6583.
31.
SpaggiariGM, CapobiancoA, AbdelrazikH, BecchettiF, MingariMC and MorettaL. (2008). Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood, 111:1327–1333.
32.
RasmussonI, Le BlancK, SundbergB and RingdenO. (2007). Mesenchymal stem cells stimulate antibody secretion in human B cells. Scand J Immunol, 65:336–343.
33.
TaberaS, Perez-SimonJA, Diez-CampeloM, Sanchez-AbarcaLI, BlancoB, LopezA, BenitoA, OcioE, Sanchez-GuijoFM, CanizoC and San MiguelJF. (2008). The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes. Haematologica, 93:1301–1309.
34.
GhannamS, PeneJ, Torcy-MoquetG, JorgensenC and YsselH. (2010). Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol, 185:302–312.
35.
KongQF, SunB, BaiSS, ZhaiDX, WangGY, LiuYM, ZhangSJ, LiR, ZhaoW, et al. (2009). Administration of bone marrow stromal cells ameliorates experimental autoimmune myasthenia gravis by altering the balance of Th1/Th2/Th17/Treg cell subsets through the secretion of TGF-beta. J Neuroimmunol, 207:83–91.
36.
BernasconiNL, TraggiaiE and LanzavecchiaA. (2002). Maintenance of serological memory by polyclonal activation of human memory B cells. Science, 298:2199–2202.
KoIK, KimBG, AwadallahA, MikulanJ, LinP, LetterioJJ and DennisJE. (2010). Targeting improves MSC treatment of inflammatory bowel disease. Mol Ther, 18:1365–1372.
39.
CiccocioppoR, BernardoME, SgarellaA, MaccarioR, AvanziniMA, UbezioC, MinelliA, AlvisiC, VanoliA, et al. (2011). Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut, 60:788–798.
40.
ChoiEW, ShinIS, ParkSY, ParkJH, KimJS, YoonEJ, KangSK, RaJC and HongSH. (2012). Reversal of serologic, immunologic, and histologic dysfunction in mice with systemic lupus erythematosus by long-term serial adipose tissue-derived mesenchymal stem cell transplantation. Arthritis Rheum, 64:243–253.
41.
YoudM, BlickarzC, WoodworthL, TouzjianT, EdlingA, TedstoneJ, RuzekM, TuboR, KaplanJ and LodieT. (2010). Allogeneic mesenchymal stem cells do not protect NZBxNZW F1 mice from developing lupus disease. Clin Exp Immunol, 161:176–186.
42.
TydenG, GenbergH, TollemarJ, EkbergH, PerssonNH, TufvesonG, WadstromJ, GabelM and MjornstedtL. (2009). A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. Transplantation, 87:1325–1329.
43.
WalshRC, AllowayRR, GirnitaAL and WoodleES. (2012). Proteasome inhibitor-based therapy for antibody-mediated rejection. Kidney Int, 81:1067–1074.
44.
MauriC and BosmaA. (2011). Immune regulatory function of B cells. Annu Rev Immunol, 30:221–241.
45.
ReichardtP, DornbachB, RongS, BeissertS, GuelerF, LoserK and GunzerM. (2007). Naive B cells generate regulatory T cells in the presence of a mature immunologic synapse. Blood, 110:1519–1529.
46.
KamarN, MiliotoO, Puissant-LubranoB, EspositoL, PierreMC, MohamedAO, LavayssiereL, CointaultO, RibesD, et al. (2010). Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am J Transplant, 10:89–98.
47.
CasiraghiF, AzzolliniN, TodeschiniM, CavinatoRA, CassisP, SoliniS, RotaC, MorigiM, IntronaM, et al. (2012). Localization of mesenchymal stromal cells dictates their immune or proinflammatory effects in kidney transplantation. Am J Transplant, 12:2373–2383.
48.
SeifertM, StolkM, PolenzD and VolkHD. (2012). Detrimental effects of rat mesenchymal stromal cell pre-treatment in a model of acute kidney rejection. Front Immunol, 3:202
49.
CarrionF, NovaE, RuizC, DiazF, InostrozaC, RojoD, MonckebergG and FigueroaFE. (2010). Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupus erythematosus patients. Lupus, 19:317–322.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
